Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aliskiren 300 mg Clear all
Terminated Phase 4 Interventional

Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients

NCT00961207
View directory record Official record
Conditions
Microalbuminuria, Macroalbuminuric Diabetic Nephropathy, Diabetes, Proteinuria, Albuminuria
Interventions
Aliskiren
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 27, 2013 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

NCT00409578
View directory record Official record
Conditions
Post Acute Coronary Syndrome, Myocardial Ischemia
Interventions
Placebo, Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Investigative Site, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 2, 2026, 6:53 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

NCT01090310
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
Beverly Hills, California • Atlanta, Georgia • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

NCT00631917
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Placebo to Ramipril, Placebo to Aliskiren
Drug · Other
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus

NCT00660309
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Aliskiren, Irbesartan, Captopril
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2012 · Synced Sep 2, 2026, 6:53 AM EDT
Not listed Phase 4 Interventional

Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension

NCT01472796
View directory record Official record
Conditions
Hypertension
Interventions
Vitamin D (cholecalciferol), Tekturna(Aliskiren) plus placebo
Dietary Supplement · Drug
Lead sponsor
Wayne State University
Other
Eligibility
30 Years to 74 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 15, 2011 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Direct Renin Inhibition Effects on Atherosclerotic Biomarkers

NCT00818779
View directory record Official record
Conditions
Coronary Artery Disease, Type 2 Diabetes Mellitus
Interventions
Aliskiren, Amlodipine
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

NCT03115853
View directory record Official record
Conditions
High Blood Pressure
Interventions
Aliskiren 150 mg, Placebo, HCTZ, Aliskiren 300 mg
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

NCT00765674
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 8, 2011 · Synced Sep 2, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

NCT00768040
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 3 Interventional

Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension

NCT00387517
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 1 Interventional Results available

Aldosterone and the Metabolic Syndrome

NCT01103245
View directory record Official record
Conditions
Metabolic Diseases, Diabetes Mellitus, Endocrine System Diseases, Glucose Metabolism Disorders
Interventions
Hydrochlorothiazide (HCTZ), Aliskiren 150 mg (ALI 150), Spironolactone (SPL 25), Aliskiren 300 mg (ALI 300), Spironolactone 50 mg (SPL 50)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Sep 2, 2026, 6:53 AM EDT
Terminated Phase 4 Interventional Results available

Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease

NCT01129557
View directory record Official record
Conditions
Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy, Focal Segmental Glomerulosclerosis, Glomerulopathy (Obesity-associated), Glomerulonephritis, Membranous
Interventions
Aliskiren, Valsartan
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 3 Interventional

A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg

NCT00171405
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 3 Interventional

A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.

NCT00219128
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)

NCT00414609
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Aliskiren, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Novartis US, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension

NCT00797316
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans

NCT00739596
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension

NCT00772577
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren Hydrochlorothiazide, Ramipril
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Beverly Hills, California • Santa Ana, California • Conyers, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

NCT00654875
View directory record Official record
Conditions
Essential Hypertension
Interventions
Aliskiren, Placebo to Aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Zanesville, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension

NCT00853957
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/Amlodipine, Amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
9
States / cities
Chicago, Illinois • Baltimore, Maryland • Oxon Hill, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population

NCT00760266
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
55 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2011 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension

NCT00809926
View directory record Official record
Conditions
Stage 2 Hypertension
Interventions
Valsartan/aliskiren, Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 1, 2011 · Synced Sep 2, 2026, 6:53 AM EDT
Completed Not applicable Interventional Results available

The Effect of Renin Inhibition on Nerve Function in Diabetes

NCT00935064
View directory record Official record
Conditions
Diabetes
Interventions
Aliskiren, Placebo
Drug · Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Sep 2, 2026, 6:53 AM EDT